Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439133 | 0.79 | IDO1 (0.46) | NOS1AXLKDM4EMEN1MAPT | |
| SCHEMBL27228475 | 0.78 | AXL (0.43) | NOS1AXLKDM4EMEN1MAPT | |
| SCHEMBL29474180 | 0.76 | NOS1 (0.55) | NOS1AXLCCNA2CDK2CCNA1 | |
| SCHEMBL14631707 | 0.76 | NOS1 (0.55) | NOS1AXLCCNA2CDK2CCNA1 | |
| SCHEMBL17681728 | 0.76 | NOS1 (0.55) | NOS1AXLCCNA2CDK2CCNA1 | |
| SCHEMBL18135157 | 0.76 | NOS1 (0.55) | NOS1AXLKMT2ACCNA2CDK2 | |
| SCHEMBL18038216 | 0.76 | NOS1 (0.50) | NOS1AXLKDM4EMEN1MAPT | |
| SCHEMBL3534803 | 0.76 | MAPT (0.52) | NOS1AXLKDM4EMEN1MAPT | |
| SCHEMBL12821601 | 0.76 | NOS1 (0.55) | NOS1AXLKDM4EMEN1MAPT | |
| SCHEMBL2005907 | 0.76 | NOS1 (0.55) | NOS1AXLCCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024199524-A1 | COMPOUND AS PKMYT1 INHIBITOR | 江苏星盛新辉医药有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-108884050-B | Tetrahydroisoquinoline derivatives | UCB生物制药私人有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-107001278-B | Tetrahydroisoquinoline derivatives | UCB生物制药私人有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-10370355-B2 | Tetrahydroisoquinoline derivatives | UCB BIOPHARMA SPRL (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20190106406-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2019-04-11 | — | — | US | disclosed |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NOS1 60/4885AXL 3109/4885KDM4E 4161/4885 |
| US-20190106406-A1 | Tetrahydroisoquinoline Derivatives | GPR52, GRK3, GPR3 | NOS1 2972/4885AXL 1556/4885KDM4E 3835/4885 |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | NOS1 2813/4885AXL 2759/4885KDM4E 3199/4885 |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | NOS1 51/4885AXL 4739/4885KDM4E 3610/4885 |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | NOS1 41/4885AXL 4757/4885KDM4E 3612/4885 |
| US-10370355-B2 | Tetrahydroisoquinoline derivatives | GPR52, GRK3, GPR3 | NOS1 2972/4885AXL 1556/4885KDM4E 3835/4885 |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | OPRD1, ADRA1D, GPR52 | NOS1 2813/4885AXL 2759/4885KDM4E 3199/4885 |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | NOS1 51/4885AXL 4739/4885KDM4E 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.